Mobile

An Open-label, Fixed-dose, Multicenter, Phase II Study of MDX-060 in Patients with Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-005547-26

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the objective response rate at Day 50 in patients with relapsed or refractory classic systemic anaplastic large cell lymphoma (csALCL) or primary cutaneous anaplastic large cell lymphoma (pcALCL) treated with MDX-060.

Critère d'inclusion

  • Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma (ALCL)

Liens